Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 101 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma MOST POPULAR Zenocutuzumab Shows Efficacy in Patients with Advanced NRG1 Fusion-positive Cancers February 19, 2025 Five Questions With…Jessica, Katie, and Melanie July 21, 2022 How our global activity is tackling cancer prevention in low- and... September 12, 2022 Study Improves the Quality of Biopsy Specimens for Cancer Research October 23, 2018 Load more HOT NEWS Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in... ESMO Highlights Key Issues for Patients with Cancer and Their Carers... With 3 Years Minimum Follow-Up, Nivolumab Plus Ipilimumab Continues to Provide... FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer
